Arrowstreet Capital’s Seres Therapeutics MCRB Stock Holding History

Arrowstreet Capital’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-728	Closed	-$125K	–	1181
2018 Q2	$125K	Sell	728 -1,836	-72%	-$300K	﹤0.01%	1027
2018 Q1	$376K	Buy	2,564 +1,859	+264%	+$357K	﹤0.01%	994
2017 Q4	$143K	Buy	+705	New	+$145K	﹤0.01%	1197

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital's MCRB Position: Q3 2018 in Review

Arrowstreet Capital sold out of Seres Therapeutics (MCRB) in Q3 2018, closing a stake of 728 shares — an estimated $125K sold.

Arrowstreet Capital first reported a position in MCRB in Q4 2017 and held it in 3 quarters. The position peaked at $376K in Q1 2018. 72 funds tracked by Wall St. Rank hold MCRB as of Q3 2018.

Arrowstreet Capital reported no remaining Seres Therapeutics position as of Q3 2018 after selling out during the quarter.
Arrowstreet Capital sold 728 Seres Therapeutics shares in Q3 2018, an estimated $125K.
Arrowstreet Capital first reported a position in Seres Therapeutics in Q4 2017 and held it in 3 quarters.
Arrowstreet Capital's Seres Therapeutics position peaked at $376K in Q1 2018.
72 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2018.

Based on Arrowstreet Capital's 13F filing for Q3 2018, filed 14 Nov 2018.